• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.伊马替尼治疗慢性髓性白血病相关的周围神经病变
Blood Res. 2018 Jun;53(2):172-174. doi: 10.5045/br.2018.53.2.172. Epub 2018 Jun 25.
2
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.慢性髓性白血病的治疗选择：伊马替尼对比干扰素对比异基因移植。
Curr Opin Oncol. 2004 Mar;16(2):95-9. doi: 10.1097/00001622-200403000-00002.
3
PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.血小板衍生生长因子受体α启动子多态性及表达模式影响慢性髓性白血病患者伊马替尼诱导的血小板减少症的发生风险：一项来自印度的研究。
Tumour Biol. 2017 Oct;39(10):1010428317713857. doi: 10.1177/1010428317713857.
4
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.新诊断慢性期慢性髓性白血病患者的最佳初始治疗
Curr Opin Hematol. 2007 Mar;14(2):138-44. doi: 10.1097/MOH.0b013e32801684a3.
5
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
6
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.伊马替尼对慢性期和急变期慢性髓性白血病患者肿瘤细胞的体外活性。
Anticancer Drugs. 2006 Jul;17(6):631-9. doi: 10.1097/01.cad.0000217423.59831.db.
7
[Imatinib therapy in chronic myeloid leukemia].[伊马替尼治疗慢性粒细胞白血病]
Orv Hetil. 2008 Aug 10;149(32):1509-12. doi: 10.1556/OH.2008.28354.
8
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.伊马替尼剂量减少在慢性髓性白血病的主要分子反应中：来自德国慢性髓性白血病研究 IV 的结果。
Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.
9
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.达沙替尼可快速诱导伊马替尼治疗后 BCR-ABL1 转录本可检测到的慢性期慢性髓性白血病患者获得主要分子学反应的深层分子反应。
Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26.
10
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.接受伊马替尼治疗的慢性粒细胞白血病或胃肠道间质瘤患者发生低丙种球蛋白血症。
Haematologica. 2008 Aug;93(8):1252-5. doi: 10.3324/haematol.12642. Epub 2008 Jun 2.

引用本文的文献

1
Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase.与使用 Janus 激酶抑制剂相关的神经系统不良事件：一项基于 Vigibase 的药物警戒研究。
Pharmaceuticals (Basel). 2025 Mar 11;18(3):394. doi: 10.3390/ph18030394.
2
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.跨领域文本挖掘以预测慢性髓性白血病酪氨酸激酶抑制剂的不良事件
Cancers (Basel). 2022 Sep 26;14(19):4686. doi: 10.3390/cancers14194686.
3
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.慢性髓性白血病中与BCR-ABL1酪氨酸激酶抑制剂相关的颅内高压
Leuk Lymphoma. 2022 Jul;63(7):1714-1717. doi: 10.1080/10428194.2022.2045599. Epub 2022 Apr 1.
4
Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib.使用三重酪氨酸激酶抑制剂尼达尼布治疗后出现的急性运动神经病伴四肢瘫痪
Respir Med Case Rep. 2021 Jul 17;34:101472. doi: 10.1016/j.rmcr.2021.101472. eCollection 2021.

本文引用的文献

1
Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.一例慢性髓性白血病患者中达沙替尼相关的可逆性脱髓鞘性周围多神经病
Int J Hematol. 2018 Mar;107(3):373-377. doi: 10.1007/s12185-017-2339-5. Epub 2017 Oct 13.
2
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.糖尿病神经病变的新视野：机制、生物能量学与疼痛
Neuron. 2017 Mar 22;93(6):1296-1313. doi: 10.1016/j.neuron.2017.02.005.
3
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.化疗诱导的周围神经病变的长期影响、病理生理机制及危险因素：一项全面的文献综述
Front Pharmacol. 2017 Feb 24;8:86. doi: 10.3389/fphar.2017.00086. eCollection 2017.
4
Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.达沙替尼继发视神经病变在1例慢性髓系白血病治疗中的情况
Saudi J Ophthalmol. 2015 Jul-Sep;29(3):227-31. doi: 10.1016/j.sjopt.2014.12.004. Epub 2015 Jan 6.
5
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.10 年期间伊马替尼治疗 CML 的安全性和疗效：来自随机 CML 研究 IV 的数据。
Leukemia. 2015 May;29(5):1123-32. doi: 10.1038/leu.2015.36. Epub 2015 Feb 13.
6
Peripheral neuropathy as an adverse effect of imatinib therapy.外周神经病变作为伊马替尼治疗的一种不良反应。
J Clin Pathol. 2011 May;64(5):456. doi: 10.1136/jcp.2010.085936. Epub 2011 Jan 28.
7
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.接受达沙替尼治疗的慢性髓性白血病患者出现的胸腔积液可能具有免疫介导的发病机制。
Br J Haematol. 2008 May;141(5):745-7. doi: 10.1111/j.1365-2141.2008.07108.x. Epub 2008 Mar 7.
8
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.癌症治疗药物甲磺酸伊马替尼的心脏毒性。
Nat Med. 2006 Aug;12(8):908-16. doi: 10.1038/nm1446. Epub 2006 Jul 23.
9
Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey.1999 - 2000年美国国家健康和营养检查调查：40岁及以上患有和未患糖尿病的美国成年人群下肢疾病患病率。
Diabetes Care. 2004 Jul;27(7):1591-7. doi: 10.2337/diacare.27.7.1591.
10
Ocular side-effects associated with imatinib mesylate (Gleevec).与甲磺酸伊马替尼（格列卫）相关的眼部副作用。
J Ocul Pharmacol Ther. 2003 Aug;19(4):371-5. doi: 10.1089/108076803322279426.

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.

作者信息

Kavanagh Simon, Bril Vera, Lipton Jeffrey H

机构信息

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

The Prosserman Family Neurology Clinic, Toronto General Hospital, University Health Network, Toronto, Canada.

出版信息

Blood Res. 2018 Jun;53(2):172-174. doi: 10.5045/br.2018.53.2.172. Epub 2018 Jun 25.

DOI:10.5045/br.2018.53.2.172
PMID:29963528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6021569/
Abstract
摘要